Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2020		146,083,110
Beginning Balance at Dec. 31, 2020	$ 134,243	$ 146	$ 1,021,221	$ (1,829)	$ (885,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(35,697)				(35,697)
Other comprehensive income, net	(1,678)			(1,678)
Recognition of stock-based compensation expense	4,212		4,212
Restricted stock award grants, net of forfeitures (in shares)		1,966,333
Restricted stock award grants, net of forfeitures	2	$ 2
Issuance of common shares (in shares)		5,678,893
Issuance of common shares	21,357	$ 6	21,351
Ending Balance (in shares) at Mar. 31, 2021		153,728,336
Ending Balance at Mar. 31, 2021	122,439	$ 154	1,046,784	(3,507)	(920,992)
Beginning Balance (in shares) at Dec. 31, 2020		146,083,110
Beginning Balance at Dec. 31, 2020	134,243	$ 146	1,021,221	(1,829)	(885,295)
Ending Balance (in shares) at Dec. 31, 2021		164,502,013
Ending Balance at Dec. 31, 2021	47,553	$ 165	1,094,353	(3,042)	(1,043,923)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(15,442)				(15,442)
Other comprehensive income, net	134			134
Recognition of stock-based compensation expense	3,011		3,011
Restricted stock award grants, net of forfeitures (in shares)		1,675,472
Restricted stock award grants, net of forfeitures	0	$ 2	(2)
Issuance of common shares (in shares)		12,500,000
Issuance of common shares	20,000	$ 12	19,988
Issuance of common stock upon vesting of performance units (in shares)		150,000
Ending Balance (in shares) at Mar. 31, 2022		178,827,485
Ending Balance at Mar. 31, 2022	$ 55,256	$ 179	$ 1,117,350	$ (2,908)	$ (1,059,365)